Individuals with neurodevelopmental disabilities (NDDs) may be at increased risk for catatonia, which can be an especially challenging condition to diagnose and treat. There may be symptom overlap between catatonia and NDD-associated behaviors, such as stereotypies. The diagnosis of catatonia should perhaps be adjusted to address symptom overlap and to include extreme behaviors observed in patients with NDDs, such as severe self-injury. Risk factors for catatonia in individuals with NDDs may include trauma and certain genetic variants, such as those that disrupt SHANK3. Common etiologic features between neurodevelopmental disabilities and catatonia, such as excitatory/inhibitory imbalance and neuroimmune dysfunction, may partially account for comorbidity. New approaches leveraging genetic testing and neuroimmunologic evaluation may allow for more precise diagnoses and effective treatments.
Catatonia is defined as “…a marked decrease in reactivity to the environment” characterized by symptoms of negativism, mutism, stupor, excitement, repeated stereotyped movements, staring, and grimacing1. It can be a severely debilitating disorder and may occur at elevated rates in patients with neurodevelopmental disabilities (NDDs), such as autism spectrum disorders (ASD), developmental delay (DD), and intellectual disability (ID)2. Current prevalence estimates of catatonia in NDDs vary widely from 6 to 20.2%3,4,5,6. Likewise, prevalence estimates in neurotypical patients vary widely depending on study design (e.g., prospective vs retrospective), location of the study (e.g., country), recruitment site (e.g., medical or psychiatric hospital or community) and psychiatric or neurologic comorbidities. In a recent meta-analysis of neurotypical clinical samples, the mean prevalence of 74 studies was 9% with a range of 1.9–48.5%7. Given the wide range prevalence estimates for both populations, it remains uncertain if catatonia is more or less common in patients with NDDs than in neurotypical populations. However, anecdotally catatonia is being increasingly recognized by clinicians who work with patients with NDDs and publication trends on the topic reflect that (Fig. 1). This increased recognition led to catatonia being added as a modifier to ASD in Diagnostic and Statistical Manual 58. So while it remains unconfirmed if individuals with NDDs have an elevated rates of catatonia, it is critical that we further our understanding of how neurobiological processes associated with NDDs may lead to a susceptibility to catatonia and what that might imply about how best to assess, diagnose, and treat catatonia in individuals with NDDs.
Many reports of patients with NDDs and catatonia discuss ASD or “autistic catatonia” specifically9,10. However, on close examination of these cases, many have complex neurodevelopmental presentations, often with low levels of premorbid functioning, suggestive of comorbid DD and/or ID in addition to ASD11 (Table 1). This entangling of NDD diagnoses makes it difficult to know if atypical neurodevelopment in the broadest sense, as compared to ASD-specific pathophysiology, may predispose individuals to catatonia.
For the purposes of this review, we highlight key points using ASD as an example, with the same principles likely applying across NDDs. We describe what is known about catatonia in NDDs, discuss underlying neurobiological factors, and explore the complicated clinical and nosological overlap of catatonia with NDDs. Finally, we propose an assessment and management approach and suggest potential future strategies to improve the understanding and treatment of catatonia in patients with NDDs. While catatonia in ASD and NDDs has been reviewed numerous times before12,13,14,15,16,17, we hope that this review adds an integrative, biologically- and evidence-based, “state-of-the-art” perspective. We highlight what we believe are the greatest needs of future research on this topic and hope to set the field on an evidence-based path forward to improve assessment, diagnosis, and treatment of patients with catatonia and NDDs.
We searched PubMed and Google Scholar using the terms: “catatonia” and (“intellectual disability” or “developmental delay” or “autism” or “neurodevelopmental disorders”) on February 14, 2022. We subsequently checked reference lists of articles and reviews until we were no longer identifying new sources. Literature published in English was selected for relevance to the topics of this Review (e.g., history, epidemiology, clinical features, treatment).
In the study of developmental psychopathology, there has long been a debate about the proper classification of certain overlapping classes of symptoms—catatonic, autistic, and psychotic—dubbed “the iron triangle”18. Early physicians had different approaches to classifying patients with a mix of psychomotor symptoms, deficits in social and language skills, and psychotic symptoms. For example, in the early 20th century the term “childhood schizophrenia” was widely used to describe a wide range of patients with a mix of these symptoms, to the point that it became so non-specific that Sir Michael Rutter urged the term to be fully retired to “the history of psychiatry” in 197219. He similarly argued for the separation of a disorder fully distinct from psychosis or schizophrenia termed autism or “infantile autism”, characterized by “failure of social development (of a specific type), a deviant and delayed language development, and various ritualistic activities”19. Karl Leonhard took a different approach to categorizing symptoms of “…stereotypies, impulsive-aggressive, self-injurious and disruptive behaviors, lack of expression, negativism, excitement, ambivalence, counter-grasping, mannerisms, peculiar speech patterns including echolalia, and neologisms…”. He classified these symptoms as “early childhood catatonia”, a subtype of “psychomotor psychoses”20. This alternative formulation through the lense of catatonia, as opposed to autism, is reflective of the overlapping symptamotolgy between these disorders. Nearly a century later, there are clearer distinction between what constitutes psychosis, autism, and catatonia, but there are certainly cases where it remains challenging to understand if new psychomotor or negativistic symptoms represent an exacerbation of preexisting neuropsychiatric symptoms or comorbid catatonia in patients with NDDs6. Thankfully, there is increasing recognition of the comorbidity between catatonia and NDDs21 and a growing body of literature on overlap of these conditions (Fig. 1).
“Classic” catatonia can be observed in patients with NDDs and may at times be straightforward to recognize and treat. However, there is often significant overlap in symptomatology between catatonic symptoms and some behaviors commonly seen in patients with NDDs. These include motor stereotypies, mannerisms, rituals, mutism, echolalia, and negativism10, which can make it challenging to distinguish an exacerbation of previous behaviors from catatonia. It is also unclear if the definition of catatonia in patients with NDDs should be altered to incorporate their neurodiversity. For example, it has been suggested that “autistic catatonia” may be best defined by freezing when carrying out actions, resistance to prompting, slow voluntary motor movements, and stopping in the course of movement22. However, this definition may capture behaviors nonspecific to catatonia and lead to overdiagnosis. It has also been suggested that extreme behaviors such as severe self-injury or unremitting tics may be uniquely indicative of catatonia in individuals with NDDs14,23. These behaviors can result in severe morbidity and impairment, and can be refractory to standard treatments, and are sometimes responsive to catatonia treatments like benzodiazepines and electroconvulsive therapy (ECT)14 However, it remains to be demonstrated whether these behaviors represent their own clinical entity or are part of the catatonia continuum for patients with NDDs. Currently, only clinical reports (and not rigorous field trials) support these behaviors as part of the catatonia syndrome in patients with NDDs, which creates the risk of confirmation and reporting bias24,25. Therefore, a rigorous assessment of the validity and reliability of expanded criteria for catatonia in NDDs is warranted.
Trauma has long been recognized as a potential risk factor for catatonia or catatonia-like states26. For example, freeze responses are observed in individuals with post-traumatic stress disorders, victims of violent assault, and those who have experienced urban violence, environmental disasters, and military combat and may represent a primitive human response to imminent doom and danger27. Likewise, a catatonic-like response to trauma and stress, defined by significant reduction in oral intake, communication, movement, and self-care, termed “Pervasive Refusal Disorder” has been described in neurotypical patients of asylum-seeking families28. It remains controversial whether this disorder is nosologically separate from catatonia29.
In patients with NDDs who may be exquisitely sensitive to their environment, disruptions to important daily routines or losses of important life figures can be highly distressing, even traumatic, and potentially triggering of catatonia. In an early study (using a very broad definition of catatonia), 2.5% of patients with NDDs and catatonia had precipitating stressors such as grief, pressures at school, and loss of structure after the environmental change (Wing & Shah, 2000). The true rate of trauma precipitating catatonia is likely higher, based on recent clinical experience and published reports (Table 1). Other traumatic experiences, such as physical abuse and parental divorce, have been associated with the emergence of catatonic symptoms in patients with ASD12,26. Although there are no current guidelines regarding the evaluation of trauma in catatonia, it may be worth considering screening patients with NDDs presenting with catatonic symptoms for recent stressors or traumas to aid diagnosis and potentially guide treatment (Fig. 2). Addressing the trauma through behavioral or other psychotherapeutic approaches may ameliorate catatonic symptoms, but that is yet to be rigorously assessed.
The heterogeneous nature of catatonia and the overlapping symptomatology with NDDs makes it challenging to create a universally generalizable and valid standardized assessment tool for all patient populations. As a results, several catatonia rating scales have been shown to have fairly low specificity30. The Bush-Francis Catatonia Rating Scale (BFCRS) is the most widely used validated catatonia rating scale in neurotypical adults and has been used in patients with NDDs as well31. An adaptation of the BFCRS, the Pediatric Catatonia Rating Scale (PCRS), is validated for pediatric patients in the inpatient setting that captures most of the same features as the BFCRS, with the exception of hyperactivity/excitement32. The Attenuated Behavior Questionnaire (ABQ)33 was developed to specifically capture the “autistic catatonia” syndrome in the outpatient setting that was previously described3. It is a 34-item, questionnaire that can be administered to caregivers of patients with ASD that has some discriminant validity for catatonia in this population33. However, the ABQ may over-estimate the prevalence of catatonia in this population (up to 48% in the original study) and likely has low specificity, given ABQ scores are positively correlated with measures of depression and repetitive/restrictive behaviors33. Therefore, the BFCRS and PCRS remain the most reliable scales to assess for catatonia in adult and pediatric patients with NDDs, respectively, and their regular implementation may help improve the consistency of future studies to improve comparability (Fig. 2).
The etiology of catatonia remains poorly understood34. However, the potentially elevated rates of catatonia in patients with NDDs and especially the overlapping symptomatology of catatonia and ASD, such as repetitive behaviors, stereotypic speech, and mannerisms, suggest that there may be common biological mechanisms underlying these conditions. Biological convergence could occur at multiple levels, including the genetic level, the neural circuit level, and/or the neuroimmune interface level (Table 2). Improving our understanding of the neurobiological overlap between NDDs and catatonia on these different scales may help us make sense of the diversity of catatonia presentations in patients with NDDs.
The degree of familial aggregation35 of catatonia (e.g., the degree to which catatonia phenotypes tend to cluster in families that cannot be accounted for by chance) varies significantly depending on how it is defined, but overall points to a strong genetic contribution36. Candidate genes (e.g., genes hypothesized to be associated with a disorder based on their biological function) such as 2′,3′-cyclic nucleotide 3′-phosphodiesterase and myelin basic protein have been implicated in catatonia through animal studies of catatonia-like behaviors and correlation of candidate genotypes with catatonia symptoms in patients with schizophrenia37. However, there are significant limitations to candidate gene studies in psychiatry38, and these associations have not, to our knowledge, been replicated in large-scale population-based genetic studies. Catatonia has been observed in patients with NDDs with established genetic etiologies39, such as Prader-Willi syndrome40, 22q13.3 deletion syndrome (Phelan-McDermid syndrome)41, Down syndrome42, 22q11.2 Deletion syndrome43, and late-onset Tay-Sachs disease44. These rare genetic disorders can shed light on the neurobiological etiology of catatonia. For example, it has been proposed that many of the genetic disorders above have convergent neurobiological disruption of the brain-specific, non-coding micro-RNA, SNORD115, that lies in the Prader-Willi/Angelman syndrome region (e.g., 15q11. 2 - q13) and plays a central role in nucleolar function45,46. SNORD115 is known to regulate the downstream effector genes of Ral GEF With PH Domain And SH3 Binding Motif 1 (RALPGS1), which subsequently modulates RAS Like Proto-Oncogenes A and B (RalA and RalB) and their binding proteins45,47. This may lead to NMDA receptor dysfunction in the postsynaptic density through altered endocytotic and autophagic lysosomal degradation45. NMDA receptor dysfunction is likewise hypothesized to underlie catatonia risk associated with SHANK3-associated disorders as it leads to alterations in cellular excitability45,48. There is potential mechanistic overlap with an ASD susceptibility locus linked with catatonia, 15q15-q21, which includes genes responsible for encoding GABA receptors B3, A5, and G349,50, again suggesting dysregulated cellular excitability may also be contributory to the pathogenesis of catatonia. This genetic evidence suggests that both catatonia and ASD may be associated with changes in Excitatory-Inhibitory (EI) balance, a circuit level dysfunction that has been observed both in animal models of catatonia and clinical settings51.
EI balance has been defined as, “…a stable global level of activity within a particular circuit, even though individual groups of neurons may exhibit transient imbalances, and these groups of neurons can be dynamic over time”51. A pathological EI imbalance that may be present in catatonia can be mediated through increased excitatory tone by local states of low dopamine, which can trigger excess glutamate release and excitotoxicity34,52. The interaction between dopamine and catatonia is further strengthened by the observation that dopamine blockade with antipsychotics can exacerbate symptoms of catatonia, and NMDA receptor blockade can conversely relieve symptoms11. Similarly, decreased inhibitory tone through GABA hypoactivity may play an important mechanistic role in catatonia53,54 that can be ameliorated through the use of GABA-ergic medications like benzodiazepines and through ECT12,26. Neuroanatomical correlates of EI dysregulation in catatonia have been studied with neuroimaging. Hypokinetic catatonia has been associated with localized hyperactivity in the supplementary and pre-supplementary motor areas, which are important in the generation and regulation of movement through interaction with the basal ganglia11,34. GABA concentration specifically within the supplementary motor areas are correlated to individual differences in motor planning, thus emphasizing the role for local EI imbalance within these particular brain structures as a potential important mechanism in catatonia and source of heterogeneity in clinical manifestation55.
Similarly, EI imbalance has been implicated in the pathogenesis of ASD51. From the integration of post-mortem and genetic analyses, it has been suggested that inhibitory hypofunction is a potential convergent pathway mechanism for the diverse pool of genetic mutations associated with synaptic dysfunction in ASD56,57. This may manifest as reduced synaptic input into inhibitory neurons, as is the case for variation in ASD-associated genes, NLGN3 and MECP2, or diminished inhibitory output on excitatory circuits, which may occur secondary to SHANK3 or TSC1 dysfunction58,59. Furthermore, reduced GABA receptor density has been observed in individuals with ASD, consistent with a theory of reduced inhibitory tone and subsequent EI imbalance60. This finding has been recapitulated in rodent models, where optogenetic modulation of cortical EI precipitates ASD-like social deficits, which are rescued by GABA agonism or NMDA antagonism61,62. On a clinical and epidemiological level, EI imbalance across brain regions is consistent with the high comorbidity between ASD and epilepsy, a disorder characterized by extreme excess of neural excitation or deficit of inhibition63. Therefore, the strong evidence for loss of inhibitory neural circuit tone in both ASD and catatonia may represent a convergent mechanism between the two disorders.
The neuroimmune axis refers to the flow of information between the immune and nervous systems that play a role in both homeostasis and a variety of disease states64. Neuroimmune dysfunction, particularly through autoimmune activation, has also been associated with both ASD and catatonia65,66. For example, autoimmune encephalitis (AIEs) of various etiologies (e.g., Anti-NMDA receptor (NMDAR); Anti-GABA-A receptor) have been observed in patients with catatonia67,68. Inflammatory physiologic disorders (e.g., systemic lupus erythematosus and thyroid disorders) have also been described in patients with catatonia66,69. NMDAR encephalitis is the autoimmune disorder most frequently associated with catatonia and serves as a potential link between neuroimmune interactions and EI balance, as discussed above66. In NMDAR encephalitis, autoantibodies target subunits on the receptors of excitatory glutamatergic neurons, causing internalization of the receptor, excitatory hypofunction, and a host of neuropsychiatric symptoms, such as psychosis, seizures, impaired cognition, and catatonia69. Interestingly, catatonia associated with NMDAR encephalitis has been effectively treated with both benzodiazepines and ECT, suggesting that strong neuromodulation may regulate immune dysfunction66. However, the impact of ECT on the neuroimmune system is complex, with some conflicting outcomes and variability depending on the chronicity of treatment and the model used. For example, a transient upregulation of neuroinflammatory cytokines, microglial activation, and an increase in the oxidative stress response are observed following acute ECT in animal models70. But in a rodent model of autoimmune encephalomyelitis, electroconvulsive seizures attenuate the innate immune system through reduced activation of T cells by microglia over time71. Therefore, repeated ECT treatments may directly counter the pro-inflammatory effects of AIE through modulation of the innate immune system in brain specific immune cell types71. These findings highlight the complex relationship between neuroimmunity, neuroinflammation, and the incompletely understood mechanisms of current catatonia treatments.
Similarly, the development of ASD has been linked to both acquired and inherited immune dysregulation72. Patients with ASD are more likely to have a family history of autoimmune conditions, such as type 1 diabetes, psoriasis, hypothyroidism, and rheumatoid arthritis73. A subset of mothers may pass maternal antibodies to their fetus during prenatal development, which has been linked to macrocephaly and ASD-related traits, such as reduced language expressivity and stereotypic behaviors73,74. Additionally, a study of monozygotic twins discordant for ASD revealed that the top differentially expressed gene across pairs was IGHG4, which codes for a surface protein on B-cells that plays a key role in immune cell activation75. This adds to a growing body of literature that demonstrates the importance of immune and inflammatory genes in ASD, such as reduced expression of genes in the complement pathway76, identification of gene networks of microglial activation that may impact synaptic transmission77, and differential impacts of microglial protein synthesis on synaptic pruning and ASD related behaviors across sexes78. Later in life, individuals with ASD are prone to developing comorbid autoimmune conditions at elevated rates, particularly with conditions that affect the nervous system, such as multiple sclerosis, myasthenia gravis, and Guillain-Barré syndrome79. Therefore, immune dysregulation through inherited and acquired factors likely plays a significant role in the pathophysiology of ASD.
Genetic testing and counseling is now recommended in the evaluation of all patients with NDDs (with or without catatonia), because of the high diagnostic yield (~35%) and increasing promise of diagnostic clarity, medical prognosis, and value to the patient and family80 (Table 3). For catatonia in patients with NDDs, genetic testing can provide additional information about the underlying etiology and even suggest specific treatments if an inborn error of metabolism, like late-onset Tay-Sachs disease44 or a SHANK3-related disorder are detected81,82. However, standard genetic testing and counseling approaches typically take weeks or months due to limited genetics providers, insurance authorization and the testing process itself. For critically ill patients with debilitating catatonia, this timeline may be insufficient. Rapid genetic testing, notably rapid whole genome sequencing (rWGS), with turnaround times of hours to days, has been shown to improve outcomes and reduce medical expenses for pediatric and neonatal intensive care patients83. It may be worth considering for the most emergent cases of catatonia, especially malignant catatonia or severe self-injury (Fig. 2). For less critical patients, standard genetic testing approaches should include methods that at least detect large genomic deletions and duplications (e.g., chromosomal microarray) and single base pair changes (e.g., exome sequencing) or those that detect both variants together (e.g., WGS), as both variant types have been associated with NDDs and catatonia39,84 (Table 3 and Fig. 2). Appropriate genetic counseling before ordering the tests and returning the results is essential to ensure informed consent/assent and optimal outcomes84,85.
AIEs such as NMDAR encephalitis, should be considered in any patient with NDDs presenting with catatonia. A standard clinical assessment looking for key features of AIEs including autonomic dysfunction, new-onset seizures, and new focal neurologic disorders, should always be performed69. However, these symptoms can sometimes be challenging to differentiate from exacerbations of pre-existing behaviors or neurologic conditions in patients with NDDs. For example, repetitive behaviors can intensify in severity that may be interpreted as hyperactive catatonia and some epilepsy syndromes can present in adolescence86, which could be mistaken for a symptom of AIE. When the rate of onset of these symptoms is rapid or subacute, an AIE should be strongly considered and a neuroimmunologic workup, including serum and cerebral spinal fluid studies for anti-neuronal autoantibodies, should be initiated87,88,89. If there is strong suspicion for an AIE in a patient with catatonia, immunomodulatory treatments, like intravenous immunoglobulins or systemic glucocorticoids87,88,89 may be considered prior to benzodiazepine or ECT treatment in order to target the underlying cause (Fig. 2). Caution should be taken in basing the diagnosis of catatonia off of treatment response alone, as individuals with catatonia due to an underlying AIE may respond to benzodiazepines or ECT treatment, but this may preclude the initiation of definitive immunomodulatory management and could result in poor long-term outcomes66. Furthermore, the diagnosis of AIE should trigger an evaluation for malignancy, as these conditions can occur as part of a paraneoplastic syndrome90.
Immunomodulatory therapies are also being actively explored in the treatment of ASD. Minocycline and Vitamin D have been shown to modulate microglial activation and improve ASD-related behaviors in animal models91,92. Given the possibility of some convergent neuroimmune mechanisms involving microglia, the question arises of whether patients with co-occurring NDD and catatonia may benefit more than neurotypical peers from immunomodulatory treatment. Four patients were recently described with SHANK3-associated NDDs (including but not limited to ASD) and comorbid neuropsychiatric symptoms, including catatonia82. They were treatment-resistant to standard psychotropics, but were rapidly responsive to immunomodulatory treatments, such as intravenous immunoglobulins, mycophenolate, and rituximab82. Larger, randomized trials are needed to clarify the role of these medications in treating patients with NDDs and catatonia, but there is growing evidence that they may especially benefit from expedient neuroimmunologic evaluation and treatment.
There is a dearth of research on the behavioral interventions for catatonia in patients with NDDs. Behavioral interventions targeting sensory, perceptual, and neurocognitive functioning have been attempted with mixed results10, but with some recent success using a “prompt-fading” approach, where behavioral interventions are slowly reduced overtime until the patient is able to function more independently93,94. Reducing stressors, providing structure throughout the day with activities that bring the patient joy, and using prompts to overcome movement difficulties improved clinician-reported ratings of movement, response, and functional independence3,95. These studies suggest that behavioral therapies may have a role in improving symptoms of mild catatonia in patients with NDDs or augmenting other treatments, but there is currently insufficient data to recommend behavioral interventions as a primary treatment approach.
The use of medications for the treatment of catatonia in neurotypical patients and patients with NDDs and catatonia follows a similar path. The gold standard pharmacotherapy continues to be benzodiazepines, such as lorazepam in doses ranging from 6–24 mg96,97. Second- and third-line agents, such as zolpidem or amantadine, for neurotypical adults currently have no safety or efficacy data in patients with NDDs and catatonia. There are preliminary reports of genetically guided treatment for catatonia, where patients with SHANK3 variants and catatonia responding positively to lithium therapy81,98 and to immunomodulation82.
For patients with catatonia that see little or no benefit from treatment with benzodiazepines, ECT remains the gold standard99. An especially high ethical bar must be met for providing ECT to patients with NDDs and catatonia, as they often cannot provide informed consent either due to their baseline intellectual disability, their acute psychiatric state, or both, and are thus highly vulnerable100. ECT might be considered earlier in the treatment algorithm if the situation is emergent, such as in the case of malignant catatonia (Fig. 2). While it is not definitively established if severe SIBs are nosologically separate from catatonia, ECT can be an effective treatment for both conditions. For example, a patient with an NDD who had 100 self-injurious episodes per hour was diagnosed with hyperactive catatonia and treated with ECT 3×/week for 5 weeks, resulting in a decreased number of episodes to 20 per hour101.
We share our perspective on some of the most important recent advances in the understanding of catatonia in patients with NDDs and highlight some of the biggest gaps in our knowledge in this state-of-the-art (non-systematic) review. While we made every effort to be comprehensive, inclusive, and unbiased in our literature search and analysis, some work invariably was given more weight than others, which is a limitation. We synthesize the current literature and propose a novel evaluation and treatment algorithm (Fig. 2) that has some similarities to previous recommendations12, but with important advancements (highlighted in blue) leveraging the most recent developments in our understanding of the behavioral, genetic, and autoimmune bases of NDDs and catatonia. We envision a future in which patients with NDDs impacted by catatonia may undergo a rapid molecular evaluation that has the potential to yield both diagnostic information and inform precision treatment plans. Due to the significant morbidity associated with severe forms of catatonia, patients stand to benefit from the rapidly improving turnaround time for genomic and serological analyses102.
A significant future challenge will be figuring out how to further refine and validate the diagnosis of catatonia for patients with NDDs, given the heterogenous presentations along with symptom overlap. The use of standardized scales in assessment and case reporting could help improve comparability of cases and aid our understanding of the progression of catatonia in the NDD population. Rigorous, prospective, multi-institutional studies will be necessary to recruit sufficiently large cohorts of patients to address these questions. As has been demonstrated for NDDs in general, a robust understanding of genetic risk factors for catatonia in NDDs could shed light on the neurobiological underpinnings103. Epigenetic studies may shed light on how psychological distress and trauma can shift neurocircuitry towards a state of catatonia in individuals with NDDs104. The use of animal or organoid models of genetic syndromes known to predispose to catatonia, such as 22q13.3 deletion syndrome or Prader–Willi Syndromes, may be particularly illuminating, as they may provide insights that generalize to idiopathic cases of NDDs105.
All data from this publication is freely available upon request
There is no code associated with this publication.
American Psychiatric Association. Desk reference to the diagnostic criteria from DSM-5™. American Psychiatric Publishing, Inc., 60–62 (2013).
Consoli, A. et al. Electroconvulsive therapy in adolescents with intellectual disability and severe self-injurious behavior and aggression: A retrospective study. Eur. Child Adolesc. Psychiatry 22, 55–62 (2013).
Wing, L. & Shah, A. Catatonia in autistic spectrum disorders. Br. J. Psychiatry 176, 357–362 (2000).
Gillberg, C. & Steffenburg, S. Outcome and prognostic factors in infantile autism and similar conditions: A population-based study of 46 cases followed through puberty. J. Autism Dev. Disord. 17, 273–287 (1987).
Ghaziuddin, N., Dhossche, D. & Marcotte, K. Retrospective chart review of catatonia in child and adolescent psychiatric patients. Acta Psychiatr. Scand. 125, 33–38 (2012).
Billstedt, E., Gillberg, C. & Gillberg, C. Autism after adolescence: Population-based 13- to 22-year follow-up study of 120 individuals with autism diagnosed in childhood. J. Autism Dev. Disord. 35, 351–360 (2005).
Solmi, M. et al. Prevalence of catatonia and its moderators in clinical samples: Results from a meta-analysis and meta-regression analysis. Schizophr. Bull. 44, 1133–1150 (2018).
Dhossche, D. M., Wilson, C. & Wachtel, L. E. Catatonia in childhood and adolescence: Implications for the DSM-5. Prim. Psychiatry 17, 35–39 (2010).
Wachtel, L. E. The multiple faces of catatonia in autism spectrum disorders: Descriptive clinical experience of 22 patients over 12 years. Eur. Child Adolesc. Psychiatry 28, 471–480 (2019).
DeJong, H., Bunton, P. & Hare, D. J. A systematic review of interventions used to treat catatonic symptoms in people with autistic spectrum disorders. J. Autism Dev. Disord. 44, 2127–2136 (2014).
Benarous, X., Raffin, M., Ferrafiat, V., Consoli, A. & Cohen, D. Catatonia in children and adolescents: New perspectives. Schizophr. Res. 200, 56–67 (2018).
Mazzone, L., Postorino, V., Valeri, G. & Vicari, S. Catatonia in patients with autism: Prevalence and management. CNS Drugs 28, 205–215 (2014).
Realmuto, G. M. & August, G. J. Catatonia in autistic disorder: A sign of comorbidity or variable expression? J. Autism Dev. Disord. 21, 517–528 (1991).
Wachtel, L. E. & Dhossche, D. M. Self-injury in autism as an alternate sign of catatonia: Implications for electroconvulsive therapy. Med. Hypotheses 75, 111–114 (2010).
Ghaziuddin, M., Quinlan, P. & Ghaziuddin, N. Catatonia in autism: A distinct subtype? J. Intellect. Disabil. Res. 49, 102–105 (2005).
Bozkurt, H. & Mukaddes, N. M. Catatonia in a child with autistic disorder. Turk. J. Pediatr. 52, 435–438 (2010).
Dhossche, D. M. Catatonia: The ultimate yet treatable motor reaction to fear in autism. Autism - Open Access 01, 1 (2012).
Shorter, E. & Wachtel, L. E. Childhood catatonia, autism and psychosis past and present: Is there an ‘iron triangle’? Acta Psychiatr. Scand. 128, 21–33 (2013).
Rutter, M. Childhood schizophrenia reconsidered. J. Autism Child. Schizophr. 2, 315–337 (1972).
Dhossche, D. M., Reti, I. M. & Wachtel, L. E. Catatonia and autism: A historical review, with implications for electroconvulsive therapy. J. ECT 25, 19–22 (2009).
Dhossche, D. M. & Wachtel, L. E. Catatonia is hidden in plain sight among different pediatric disorders: A review article. Pediatr. Neurol. 43, 307–315 (2010).
Hare, D. J. & Malone, C. Catatonia and autistic spectrum disorders. Autism 8, 183–195 (2004).
Cavanna, A. E., Robertson, M. M. & Critchley, H. D. Catatonic signs in Gilles de la Tourette syndrome. Cogn. Behav. Neurol. 21, 34–37 (2008).
Nickerson, R. S. Confirmation bias: A ubiquitous phenomenon in many guises. Rev. Gen. Psychol. 2, 175–220 (1998).
Dwan, K. et al. Systematic review of the empirical evidence of study publication bias and outcome reporting bias. PLoS One 3, e3081 (2008).
Dhossche, D. M., Ross, C. A. & Stoppelbein, L. The role of deprivation, abuse, and trauma in pediatric catatonia without a clear medical cause. Acta Psychiatr. Scand. 125, 25–32 (2012).
Moskowitz, A. K. Scared stiff’: Catatonia as an evolutionary-based fear response. Psychol. Rev. 111, 984 (2004).
Lask, B. Pervasive refusal syndrome. Adv. Psychiatr. Treat. 10, 153–159 (2004).
Dhossche, D. & Kellner, C. H. Pervasive refusal syndrome: A misnomer for catatonia. Asian J. Psychiatr. 18, 113 (2015).
Kirkhart, R. et al. The detection and measurement of catatonia. Psychiatry 4, 52 (2007).
Carroll, B. T. et al. Katatonia: A new conceptual understanding of catatonia and a new rating scale. Psychiatry 5, 42 (2008).
Benarous, X. et al. Validation of the Pediatric Catatonia Rating Scale (PCRS). Schizophr. Res. 176, 378–386 (2016).
Breen, J. & Hare, D. J. The nature and prevalence of catatonic symptoms in young people with autism. J. Intellect. Disabil. Res. 61, 580–593 (2017).
Walther, S., Stegmayer, K., Wilson, J. E. & Heckers, S. Structure and neural mechanisms of catatonia. Lancet Psychiatry 6, 610–619 (2019).
Zimmerman, R., Pal, D. K., Tin, A., Ahsan, H. & Greenberg, D. A. Methods for assessing familial aggregation: Family history measures and confounding in the standard cohort, reconstructed cohort and case-control designs. Hum. Hered. 68, 201 (2009).
Peralta, V., Fañanás, L., Martin-Reyes, M. & Cuesta, M. J. Dissecting the catatonia phenotype in psychotic and mood disorders on the basis of familial-genetic factors. Schizophr. Res. 200, 20–25 (2018).
Janova, H. et al. Microglia ablation alleviates myelin-associated catatonic signs in mice. J. Clin. Invest. 128, 734–745 (2018).
Liu, C. et al. The schizophrenia genetics knowledgebase: A comprehensive update of findings from candidate gene studies. Transl. Psychiatry 9, 205 (2019).
Raffin, M. et al. Catatonia in children and adolescents: A high rate of genetic conditions. J. Am. Acad. Child Adolesc. Psychiatry 57, 518–525.e1 (2018).
Poser, H. M. & Trutia, A. E. Treatment of a Prader-Willi patient with recurrent catatonia. Case Rep. Psychiatry 2015, 697428 (2015).
Verhoeven, W. M. A., Egger, J. I. M. & de Leeuw, N. A longitudinal perspective on the pharmacotherapy of 24 adult patients with Phelan McDermid syndrome. Eur. J. Med. Genet. 63, 103751 (2020).
Miles, J. H., Takahashi, N., Muckerman, J., Nowell, K. P. & Ithman, M. Catatonia in down syndrome: Systematic approach to diagnosis, treatment and outcome assessment based on a case series of seven patients. Neuropsychiatr. Dis. Treat. 15, 2723–2741 (2019).
Butcher, N. J. et al. Neuropsychiatric expression and catatonia in 22q11.2 deletion syndrome: An overview and case series. Am. J. Med. Genet. Part A 176, 2146–2159 (2018).
Walterfang, M., Bonnot, O., Mocellin, R. & Velakoulis, D. The neuropsychiatry of inborn errors of metabolism. J. Inherit. Metab. Dis. 36, 687–702 (2013).
Peter-Ross, E. M. Molecular hypotheses to explain the shared pathways and underlying pathobiological causes in catatonia and in catatonic presentations in neuropsychiatric disorders. Med. Hypotheses 113, 54–64 (2018).
Bortolin-Cavaillé, M. L. & Cavaillé, J. The SNORD115 (H/MBII-52) and SNORD116 (H/MBII-85) gene clusters at the imprinted Prader–Willi locus generate canonical box C/D snoRNAs. Nucleic Acids Res. 40, 6800–6807 (2012).
Gentry, L. R., Martin, T. D., Reiner, D. J. & Der, C. J. Ral small GTPase signaling and oncogenesis: More than just 15 min of fame. Biochim. Biophys. Acta - Mol. Cell Res. 1843, 2976–2988 (2014).
Breckpot, J. et al. Copy number variation analysis in adults with catatonia confirms haploinsufficiency of SHANK3 as a predisposing factor. Eur. J. Med. Genet. 59, 436–443 (2016).
Dhossche, D. M., Song, Y. & Liu, Y. Is there a connection between autism, Prader-Willi syndrome, catatonia, and GABA? Int. Rev. Neurobiol. 71, 189–216 (2005).
Chagnon, Y. C. Shared susceptibility region on chromosome 15 between autism and catatonia. Int. Rev. Neurobiol. 72, 165–178 (2006).
Sohal, V. S. & Rubenstein, J. L. R. Excitation-inhibition balance as a framework for investigating mechanisms in neuropsychiatric disorders. Mol. Psychiatry 2019 249 24, 1248–1257 (2019).
Parenti, A., Jardri, R. & Geoffroy, P. A. How anti-NMDAR encephalitis sheds light on the mechanisms underlying catatonia: The neural excitatory/inhibitory imbalance model. Psychosomatics 57, 336–338 (2016).
Northoff, G. et al. Decreased density of GABA-A receptors in the left sensorimotor cortex in akinetic catatonia: investigation of in vivo benzodiazepine receptor binding. J. Neurol. Neurosurg. Psychiatry 67, 445–450 (1999).
Dhossche, D. M., Stoppelbein, L. & Rout, U. K. Etiopathogenesis of catatonia: Generalizations and working hypotheses. J. ECT 26, 253–258 (2010).
Boy, F. et al. Individual differences in subconscious motor control predicted by GABA concentration in SMA. Curr. Biol. 20, 1779–1785 (2010).
de la Torre-Ubieta, L., Won, H., Stein, J. L. & Geschwind, D. H. Advancing the understanding of autism disease mechanisms through genetics. Nat. Med. 22, 345–361 (2016).
Selten, M., van Bokhoven, H. & Kasri, N. N. Inhibitory control of the excitatory/inhibitory balance in psychiatric disorders. F1000Research 7, 23 (2018).
Lee, J. et al. Shank3-mutant mice lacking exon 9 show altered excitation/inhibition balance, enhanced rearing, and spatial memory deficit. Front. Cell. Neurosci. 9, 94 (2015).
Bateup, H. S. et al. Excitatory/inhibitory synaptic imbalance leads to hippocampal hyperexcitability in mouse models of tuberous sclerosis. Neuron 78, 510–522 (2013).
Oblak, A. L., Gibbs, T. T. & Blatt, G. J. Decreased GABAB receptors in the cingulate cortex and fusiform gyrus in autism. J. Neurochem. 114, 1414–1423 (2010).
Yizhar, O. et al. Neocortical excitation/inhibition balance in information processing and social dysfunction. Nature 477, 171–178 (2011).
Won, H. et al. Autistic-like social behaviour in Shank2-mutant mice improved by restoring NMDA receptor function. Nature 486, 261–265 (2012).
Canitano, R. Epilepsy in autism spectrum disorders. Eur. child Adolesc. psychiatry 16, 61–66 (2007).
Huh, J. R. & Veiga-Fernandes, H. Neuroimmune circuits in inter-organ communication. Nat. Rev. Immunol. 20, 217–228 (2020).
Wu, S. et al. Family history of autoimmune diseases is associated with an increased risk of autism in children: A systematic review and meta-analysis. Neurosci. Biobehav. Rev. 55, 322–332 (2015).
Rogers, J. P., Pollak, T. A., Blackman, G. & David, A. S. Catatonia and the immune system: A review. Lancet Psychiatry 6, 620–630 (2019).
Espinola-Nadurille, M. et al. Catatonia in patients with anti-NMDA receptor encephalitis. Psychiatry Clin. Neurosci. 73, 574–580 (2019).
Samra, K., Rogers, J., Mahdi-Rogers, M. & Stanton, B. Catatonia with GABAA receptor antibodies. Pract. Neurol. 20, 139–143 (2020).
Dalmau, J. & Graus, F. Antibody-mediated encephalitis. N. Engl. J. Med. 378, 840–851 (2018).
An, X. & Shi, X. Effects of electroconvulsive shock on neuro-immune responses: Does neuro-damage occur? Psychiatry Res. 292, 113289 (2020).
Goldfarb, S., Fainstein, N. & Ben-Hur, T. Electroconvulsive stimulation attenuates chronic neuroinflammation. JCI insight 5, e137028 (2020).
Edmiston, E., Ashwood, P. & de Water, J. Autoimmunity, autoantibodies, and autism spectrum disorder. Biol. Psychiatry 81, 383–390 (2017).
Nordahl, C. W. et al. Maternal autoantibodies are associated with abnormal brain enlargement in a subgroup of children with autism spectrum disorder. Brain. Behav. Immun. 30, 61–65 (2013).
Braunschweig, D. et al. Behavioral correlates of maternal antibody status among children with autism. J. Autism Dev. Disord. 42, 1435–1445 (2012).
Saffari, A. et al. RNA sequencing of identical twins discordant for autism reveals blood-based signatures implicating immune and transcriptional dysregulation. Mol. Autism 10, 1–15 (2019).
Fagan, K., Crider, A., Ahmed, A. O. & Pillai, A. Complement C3 expression is decreased in autism spectrum disorder subjects and contributes to behavioral deficits in rodents. Mol. Neuropsychiatry 3, 19–27 (2017).
Gupta, S. et al. Transcriptome analysis reveals dysregulation of innate immune response genes and neuronal activity-dependent genes in autism. Nat. Commun. 5, 1–8 (2014).
Xu, Z.-X. et al. Elevated protein synthesis in microglia causes autism-like synaptic and behavioral aberrations. Nat. Commun. 11, 1–17 (2020).
Spann, M. N. et al. Proband and familial autoimmune diseases are associated with proband diagnosis of autism spectrum disorders. J. Am. Acad. Child Adolesc. Psychiatry 58, 496–505 (2019).
Manickam, K. et al. Exome and genome sequencing for pediatric patients with congenital anomalies or intellectual disability: An evidence-based clinical guideline of the American College of Medical Genetics and Genomics (ACMG). Genet. Med. https://doi.org/10.1038/s41436-021-01242-6 (2021).
Serret, S. et al. Lithium as a rescue therapy for regression and catatonia features in two SHANK3 patients with autism spectrum disorder: Case reports. BMC Psychiatry 15, 107 (2015).
Bey, A. L. et al. Subacute neuropsychiatric syndrome in girls with SHANK3 mutations responds to immunomodulation. Pediatrics 145, e20191490 (2020).
Dimmock, D. P. et al. An RCT of rapid genomic sequencing among seriously Ill infants results in high clinical utility, changes in management, and low perceived harm. Am. J. Hum. Genet. 107, 942–952 (2020).
Nurnberger, J. I. et al. What should a psychiatrist know about genetics? Review and recommendations from the residency education committee of the international society of psychiatric genetics. J. Clin. Psychiatry 80, 17nr12046 (2019).
Moldovan, R., Pintea, S. & Austin, J. The efficacy of genetic counseling for psychiatric disorders: A meta-analysis. J. Genet. Couns. 26, 1341–1347 (2017).
Vorderwülbecke, B. J. et al. Long-term outcome in adolescent-onset generalized genetic epilepsies. Epilepsia 58, 1244–1250 (2017).
Lancaster, E. The diagnosis and treatment of autoimmune encephalitis. J. Clin. Neurol. 12, 1 (2016).
Abboud, H. et al. Autoimmune encephalitis: Proposed recommendations for symptomatic and long-term management. J. Neurol. Neurosurg. Psychiatry 92, 897–907 (2021).
Zuliani, L. et al. Management of antibody-mediated autoimmune encephalitis in adults and children: Literature review and consensus-based practical recommendations. Neurol. Sci. 40, 2017–2030 (2019).
Gultekin, S. H. et al. Paraneoplastic limbic encephalitis: Neurological symptoms, immunological findings and tumour association in 50 patients. Brain 123, 1481–1494 (2000).
Zhu, F. et al. Minocycline and risperidone prevent microglia activation and rescue behavioral deficits induced by neonatal intrahippocampal injection of lipopolysaccharide in rats. PLoS One 9, e93966 (2014).
Boontanrart, M., Hall, S. D., Spanier, J. A., Hayes, C. E. & Olson, J. K. Vitamin D3 alters microglia immune activation by an IL-10 dependent SOCS3 mechanism. J. Neuroimmunol. 292, 126–136 (2016).
Vener, S. M., Wichnick-Gillis, A. M., Badala, D. & Poulson, C. L. Increasing behavior incompatible with catatonia in a young adolescent girl with autism spectrum disorder. Res. Autism Spectr. Disord. 57, 7–18 (2019).
Vener, S. M., Gillis, A. M. & Poulson, C. L. Increasing verbal behavior in a young adolescent girl with catatonia and autism spectrum disorder. J. Autism Dev. Disord. 51, 3857–3867 (2021).
Dhossche, D. M., Shah, A. & Wing, L. Blueprints for the assessment, treatment, and future study of catatonia in autism spectrum disorders. Int. Rev. Neurobiol. 72, 267–284 (2006).
Raffin, M. et al. Treatment use in a prospective naturalistic cohort of children and adolescents with catatonia. Eur. Child Adolesc. Psychiatry 24, 441–449 (2015).
Fink, M. & Taylor, M. A. Catatonia: A Clinician’s Guide to Diagnosis and Treatment (Cambridge University Press, 2006).
Egger, J. I. M., Verhoeven, W. M. A., Groenendijk-Reijenga, R. & Kant, S. G. Phelan-McDermid syndrome due to SHANK3 mutation in an intellectually disabled adult male: Successful treatment with lithium. BMJ Case Rep. 2017, bcr2017220778 (2017).
Weder, N. D., Muralee, S., Penland, H. & Tampi, R. R. Catatonia: A review. Ann. Clin. Psychiatry 20, 97–107 (2008).
Thuppal, M. & Fink, M. Electroconvulsive therapy and mental retardation. J. ECT 15, 140–149 (1999).
Wachtel, L. E. et al. ECT for self-injury in an autistic boy. Eur. Child Adolesc. Psychiatry 18, 458–463 (2009).
Dimmock, D. et al. Project baby bear: Rapid precision care incorporating rWGS in 5 California children’s hospitals demonstrates improved clinical outcomes and reduced costs of care. Am. J. Hum. Genet. 108, 1231–1238 (2021).
Sanders, S. J. et al. Insights into autism spectrum disorder genomic architecture and biology from 71 risk Loci. Neuron 87, 1215–1233 (2015).
Chaby, L. E. et al. Repeated stress exposure in mid-adolescence attenuates behavioral, noradrenergic, and epigenetic effects of trauma-like stress in early adult male rats. Sci. Rep. 10, 1–11 (2020).
Kelley, K. W. & Pașca, S. P. Human brain organogenesis: Toward a cellular understanding of development and disease. Cell 185, 42–61 (2022).
Quilliam, R., Quilliam, S., Turnbull, M., Parkinson, S. & Oligbu, G. Catatonia as a presentation of autism in a child: A case report. AIMS Neurosci. 7, 327 (2020).
Withane, N. & Dhossche, D. M. Electroconvulsive treatment for catatonia in autism spectrum disorders. Child Adolesc. Psychiatr. Clin. N Am. 28, 101–110 (2019).
Quigley, J., Lommel, K. M. & Coffey, B. Catatonia in an adolescent with Asperger’s disorder. J. Child Adolesc. Psychopharmacol. 19, 93–96 (2009).
Wachtel, L. E., Kahng, S. W., Dhossche, D. M., Cascella, N. & Reti, I. M. ECT for catatonia in an autistic girl. Am. J. Psychiatry 165, 329–333 (2008).
Wachtel, L. E., Griffin, M. M., Dhossche, D. M. & Reti, I. M. Brief report: Electroconvulsive therapy for malignant catatonia in an autistic adolescent. Autism 14, 349–358 (2010).
Haq, A. U. & Ghaziuddin, N. Maintenance electroconvulsive therapy for aggression and self-injurious behavior in two adolescents with autism and catatonia. J. Neuropsychiatry Clin. Neurosci. 26, 64–72 (2014).
Vorstman, J. A. S. et al. Autism genetics: Opportunities and challenges for clinical translation. Nat. Rev. Genet. 18, 362–376 (2017).
Consoli, A. et al. Medical and developmental risk factors of catatonia in children and adolescents: A prospective case-control study. Schizophr. Res. 137, 151–158 (2012).
Thee authors would like to thank the UCSD Department of Psychiatry, Rady Children’s Hospital San Diego Division of Behavioral Health Services, and the Rady Children’s Institute for Genomic Medicine for their support.
The authors declare no competing interests.
Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
About this article
Cite this article
Moore, S., Amatya, D.N., Chu, M.M. et al. Catatonia in autism and other neurodevelopmental disabilities: a state-of-the-art review. npj Mental Health Res 1, 12 (2022). https://doi.org/10.1038/s44184-022-00012-9